Product name as reported
Cannabis Sativa Subsp Indica Top: adverse event reports filed with FDA
6,880 reports list it as a suspect or interacting product, 2011–2026.
- 6,880
- reports as suspect product
- 0% of all reports · about 467 a year
- 1,801
- reports, 12 months to June 2026
- 1,435 in the 12 months before
- 93%
- marked serious by the reporter
- 57.4% across all reports
- 30.5%
- record death among outcomes, as reported
- 2,096 reports · not verified by FDA
6,880 adverse event reports received by FDA list the product name "Cannabis Sativa Subsp Indica Top" as reporters wrote it as a suspect or interacting product, from October 2011 to June 2026. A further 2,694 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 1,801 reports listed it, up 26% from 1,435 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 467 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
The reactions recorded most often are drug abuse (39.3%), substance use disorder (15.5%) and drug use disorder (14.1%). A report can list several reactions, so shares add to more than 100%; 799 different terms appear across these reports. Drug abuse is recorded in 39.3% of these reports, against 0.4% of all reports in the database.
93% of the reports are marked serious by the reporter; 30.5% record death among the outcomes and 30.5% record hospitalisation, as reported. 46.2% of the reports came from physicians, and the largest patient age group is 18 to 44 (60.6%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Cannabis Sativa Subsp Indica Top reports recording the termall reports in the database
- Drug abusemisuse of a medicine39.3%2,704
- Substance use disorder15.5%1,069
- Drug use disorder14.1%973
- Toxicity to various agentspoisoning or toxic effect of one or more substances8.7%601
- Coma8%550
- Somnolencedrowsiness7.1%488
- Drug diversion6.9%472
- Drug dependencedependence on a medicine6.8%470
- Miosis6%415
- Deaththe patient died; cause not stated by this term4.9%339
- Agitationrestlessness4.8%332
- Mydriasis4.1%283
- Intentional product misusedeliberate use not as intended4.1%280
- Completed suicidedeath by suicide4.1%279
- Tachycardiafast heart rate3.9%269
- Aggressionaggressive behaviour3.3%226
- Poisoning3.1%216
- Suicidal ideationthoughts of suicide2.8%191
- Hypotensionlow blood pressure2.7%186
- Cardio-respiratory arrestthe heart and breathing stopped2.6%181
- Vomitingbeing sick2.6%181
- Substance abuse2.5%170
- Loss of consciousnesspassing out2.4%167
- Poisoning deliberate2.4%166
- Anxietyanxiety2.4%164
- Drug interactionan interaction between medicines2.3%159
- Suicide attempta suicide attempt2.2%152
- Drug screen positive2.2%150
- Headachehead pain2.2%150
Top 30 of 799 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 38.3% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Drug abuse | 212 | 3.1% |
| Pain | 51 | 0.7% |
| Suicide attempt | 42 | 0.6% |
| Substance use | 19 | 0.3% |
| Insomnia | 18 | 0.3% |
| Neuralgia | 14 | 0.2% |
The indication field is filled in by the reporter and is often blank; shares are of all 6,880 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Cannabis Sativa Subsp Indica Top reports |
|---|---|---|
| Cocaine | 2,493 | 36.2% |
| Alcohol | 1,366 | 19.9% |
| Diazepam | 1,202 | 17.5% |
| Fentanyl | 1,088 | 15.8% |
| Pregabalin | 1,053 | 15.3% |
| Alprazolam | 710 | 10.3% |
| Clonazepam | 631 | 9.2% |
| Methamphetamine | 605 | 8.8% |
| Tramadol | 570 | 8.3% |
| Buprenorphine | 492 | 7.2% |
Other products listed in reports where Cannabis Sativa Subsp Indica Top is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Cannabis Sativa Subsp Indica Top | All reports |
|---|---|---|
| Reports as suspect product | 6,880 | 20,646,523 |
| Share of that pool | — | 0% |
| Reports, latest 12 months | 1,801 | 1,332,454 |
| Marked serious | 93% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 305 | 91 |
| Hospitalisation recorded, per 1,000 reports | 305 | 213 |
| Consumer-filed share | 15.5% | 45.8% |
| Top term, share of reports | Drug abuse 39.3% | 0.4% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Cannabis Sativa Subsp Indica Top reports
How many adverse event reports has FDA received for Cannabis Sativa Subsp Indica Top?
6,880 reports list Cannabis Sativa Subsp Indica Top as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 1,801 of them arrived in the latest 12 months. Another 2,694 list it only as a concomitant medication.
What reactions are recorded in Cannabis Sativa Subsp Indica Top reports?
drug abuse (39.3%), substance use disorder (15.5%), drug use disorder (14.1%), toxicity to various agents (8.7%) and coma (8%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Cannabis Sativa Subsp Indica Top was responsible.
How serious are the reports?
93% are marked serious by the reporter. Among the outcomes recorded, 30.5% of reports include death and 30.5% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
physician (46.2%), pharmacist (24.9%) and consumer or non-health professional (15.5%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Cannabis Sativa Subsp Indica Top rising?
1,801 reports in the 12 months to June 2026, up 26% from 1,435 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Cannabis Sativa Subsp Indica Top was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Cannabis Sativa Subsp Indica Top?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Cannabis Sativa Subsp Indica Top as a suspect or interacting product; reports listing it only as a concomitant medication (2,694) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.